UNIVEST FINANCIAL Corp Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Key Points

• UNIVEST FINANCIAL Corp increased its stake in Eli Lilly and Company by 468.7%, acquiring an additional 14,784 shares, thus holding a total of 17,938 shares valued at approximately $14.8 million.
• Despite a significant increase in institutional ownership, Eli Lilly's stock has faced mixed ratings, with HSBC lowering its rating from "buy" to "reduce" and Goldman Sachs upgrading it to "buy," with a consensus rating of "Moderate Buy."
• Eli Lilly recently reported earnings of $3.34 per share, missing estimates by $1.30, and also announced a quarterly dividend of $1.50 per share, reflecting a 0.8% yield.

UNIVEST FINANCIAL Corp raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 468.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,938 shares of the company's stock after purchasing an additional 14,784 shares during the quarter. Eli Lilly and Company accounts for 1.0% of UNIVEST FINANCIAL Corp's investment portfolio, making the stock its 21st largest position. UNIVEST FINANCIAL Corp's holdings in Eli Lilly and Company were worth $14,815,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of LLY. Applied Finance Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 1.4% during the 4th quarter. Applied Finance Capital Management LLC now owns 855 shares of the company's stock valued at $660,000 after buying an additional 12 shares in the last quarter. Garner Asset Management Corp raised its holdings in shares of Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock valued at $411,000 after buying an additional 12 shares in the last quarter. Tobias Financial Advisors Inc. raised its holdings in shares of Eli Lilly and Company by 4.1% during the 4th quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company's stock valued at $237,000 after buying an additional 12 shares in the last quarter. Redwood Investments LLC raised its holdings in shares of Eli Lilly and Company by 0.5% during the 4th quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock valued at $1,705,000 after buying an additional 12 shares in the last quarter. Finally, Hobbs Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 0.8% during the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after buying an additional 12 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 2.9%

NYSE:LLY traded up $21.40 during trading hours on Friday, hitting $761.47. The company's stock had a trading volume of 4,857,388 shares, compared to its average volume of 3,285,034. The stock has a market capitalization of $721.68 billion, a P/E ratio of 55.40, a price-to-earnings-growth ratio of 1.08 and a beta of 0.44. The stock has a fifty day moving average of $775.51 and a 200-day moving average of $799.86. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter last year, the company posted $2.58 EPS. Eli Lilly and Company's quarterly revenue was up 45.2% on a year-over-year basis. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price target for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. UBS Group dropped their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their target price for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.